Soleno Therapeutics
SLNO
SLNO was delisted on the 15th of May, 2026.
225 hedge funds and large institutions have $2.08B invested in Soleno Therapeutics in 2026 Q1 according to their latest regulatory filings, with 44 funds opening new positions, 91 increasing their positions, 69 reducing their positions, and 60 closing their positions.
32% more repeat investments, than reductions
Existing positions increased: 91 | Existing positions reduced: 69
0.28% less ownership
Funds ownership: 120.89% → 120.6% (-0.28%)
9% less funds holding
Funds holding: 248 → 225 (-23)
27% less first-time investments, than exits
New positions opened: 44 | Existing positions closed: 60
31% less capital invested
Capital invested by funds: $3.01B → $2.08B (-$925M)
40% less call options, than puts
Call options by funds: $52M | Put options by funds: $87M
44% less funds holding in top 10
Funds holding in top 10: 9 → 5 (-4)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
KCM
Khrom Capital Management
Miami Beach,
Florida
|
+$59.3M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
+$43.3M |
| 3 |
VPC
Vestal Point Capital
New York
|
+$28.6M |
| 4 |
PCH
Polar Capital Holdings
London,
United Kingdom
|
+$22M |
| 5 |
KCM
Kynam Capital Management
Princeton,
New Jersey
|
+$22M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$89.9M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$89.8M |
| 3 |
Invesco
Atlanta,
Georgia
|
-$32.5M |
| 4 |
Millennium Management
New York
|
-$24.7M |
| 5 |
ACA
Avoro Capital Advisors
New York
|
-$23.5M |
SLNO Hedge Fund Activity: Q1 2026 in Review
225 of the 8,172 institutional investors tracked by Wall St. Rank reported a position in Soleno Therapeutics (SLNO) for Q1 2026, worth a combined $2.08B — down 31% from $3.01B a quarter earlier.
Sellers outnumbered buyers: 60 funds closed out of SLNO and 44 opened new positions — a net loss of 16 holders — while 69 trimmed existing stakes and 91 added.
The largest buyer was Khrom Capital Management, opening a new position worth an estimated $59.3M. The largest seller was T. Rowe Price Associates, cutting an estimated $89.9M.
- 225 institutional investors held Soleno Therapeutics (SLNO) as of Q1 2026, down from 248 in Q4 2025.
- Funds reported $2.08B of Soleno Therapeutics stock for Q1 2026, down 31% quarter-over-quarter.
- 44 funds opened new Soleno Therapeutics positions in Q1 2026 and 60 closed out, a net change of -16 holders.
- The largest Soleno Therapeutics buyer in Q1 2026 was Khrom Capital Management, an estimated $59.3M added.
- The largest Soleno Therapeutics seller in Q1 2026 was T. Rowe Price Associates, an estimated $89.9M sold.
Based on aggregated 13F filings for Q1 2026.